Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

Figure 1

Clinical improvement during follow up in nine systemic sclerosis patients treated with anti-CD20. Clinical improvement in the nine patients treated with anti-CD20 during the follow-up times (3, 6, 12, 18, 24 and 36 months). Skin score, blood CD20 levels, severity index and activity index were assessed at baseline (0) and after 3, 6, 12, 18, 24 and 36 months. In the first graph precyclophosphamide (preCYP) skin score and skin score at time 0 (time of beginning of rituximab (RTX)) are reported. Each line represents the modification of different parameters in each patient during the follow up. Each symbol (on the left) represents one patient and corresponds to the number of the patient of Table 3.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us